AstraZeneca Annual Report and 36 Form 20-F Information 2005 DEVELOPMENT PIPELINE AT 2 FEBRUARY 2006 Estimated filing date Therapy area Compound Mechanism Areas under investigation Europe US PRE-CLINICAL: NCEs CV AZD8450 dyslipidaemia 2008 2008 CV AZD6370 diabetes 2008 2008 CV AZD8593 haemostasis 2008 2008 CV AZD1175 diabetes obesity 2008 2008 CV AZD2207 diabetes obesity 2008 2008 CV AZD1305 arrhythmias 2008 2008 CV AZD1092 diabetes 2008 2008 CV AZD4121 dyslipidaemia 2008 2008 GI AZD8081 functional GI disease 2008 2008 GI AZD6538 GERD 2008 2008 Neuroscience AZD3102 Alzheimers disease 2008 2008 Neuroscience AZD1080 Alzheimers disease 2008 2008 Neuroscience AZD2327 anxiety 2008 2008 Neuroscience AZD5904 multiple sclerosis 2008 2008 Neuroscience AZD6538 neuropathic pain 2008 2008 Neuroscience AZD8797 multiple sclerosis 2008 2008 Neuroscience AZD3783 anxiety and depression 2008 2008 Neuroscience AZD1940 nociceptive and neuropathic pain 2008 2008 Neuroscience AZD9335 neuropathic pain 2008 2008 Neuroscience AZD3241 Parkinsons disease 2008 2008 Oncology AZD9935 VEGFR-TKI solid tumours 2008 2008 Oncology AZD0424 SRC kinase inhibitor solid tumours 2008 2008 Oncology AZD8931 solid tumours 2008 2008 Oncology AZD4877 solid tumours 2008 2008 Oncology AZD7762 solid tumours 2008 2008 Oncology AZD5180 Abgenix solid tumours 2008 2008 Oncology AZD1845 solid tumours 2008 2008 Oncology AZD8330 solid tumours 2008 2008 Oncology AZD3646 solid tumours and haematological malignancies 2008 2008 R&I AZD6067 protease inhibitor COPD 2008 2008 R&I AZD6703 rheumatoid arthritis 2008 2008 R&I AZD6357 osteoarthritis 2008 2008 R&I AZD7928 COPD 2008 2008 R&I AZD2914 COPD 2008 2008 R&I AZD2392 asthma rhinitis 2008 2008 R&I AZD1744 asthma rhinitis 2008 2008 R&I AZD5672 rheumatoid arthritis 2008 2008 R&I AZD3825 asthma 2008 2008 R&I AZD1236 COPD 2008 2008 R&I AZD4818 COPD 2008 2008 R&I AZD5069 COPD 2008 2008 R&I AZD9668 COPD 2008 2008 R&I AZD9215 asthma 2008 2008 R&I AZD1678 asthma 2008 2008 R&I AZD6605 osteoarthritis 2008 2008 PHASE 1: NCEs CV AZD2479 Avanir reverse cholesterol transport enhancer dyslipidaemia 2008 2008 CV AZD6610 dyslipidaemia diabetes 2008 2008 CV AZD8677 dyslipidaemia diabetes 2008 2008 GI AZD3355 TLESR GERD 2008 2008 GI AZD9343 TLESR GERD 2008 2008 GI AZD9272 GERD 2008 2008 Neuroscience AZD9272 neuropathic pain 2008 2008 Oncology AZD0530 SRC kinase inhibitor solid tumours and haematological malignancies 2008 2008 Oncology AZD6244 ARRY-142886 MEK inhibitor solid tumours 2008 2008 Oncology AZD1152 aurora kinase inhibitor solid tumours and haematological malignancies 2008 2008 Oncology AZD4769 solid tumours 2008 2008 Oncology KU59436 KuDOS PARP inhibitor breast cancer 2008 2008 Oncology AQ4N KuDOS hypoxia activated cytotoxic solid tumours 2008 2008 Abbreviations used in the above tables are explained on page 35. Business Review 37 Estimated filing date Therapy area Compound Mechanism Areas under investigation Europe US PHASE 1: NCEs CONTINUED R&I AZD8309 chemokine receptor antagonist rheumatoid arthritis 2008 2008 R&I AZD8309 chemokine receptor antagonist COPD 2008 2008 R&I AZD3342 protease inhibitor COPD 2008 2008 R&I AZD1981 asthma 2008 2008 PHASE 2: NCEs CV AZD7009 anti-arrhythmic IV atrial fibrillation conversion 2008 2008 CV AZD9684 CPU inhibitor thrombosis 2008 2008 CV AZD0837 thrombin inhibitor thrombosis 2008 2008 GI AZD9056 ion channel blocker inflammatory bowel disease 2008 2008 Neuroscience AZD3480 TC-1734 Targacept NNR agonist cognitive disorders 2008 2008 Oncology Zactima ZD6474 VEGF EGF TKI inhibitor with RET kinase activity medullary thyroid cancer 2008 2008 Oncology Patrin KuDOS AGT inhibitor solid tumours 2008 2008 Oncology ZD4054 endothelin A receptor antagonist prostate cancer 2008 2008 R&I AZD9056 ion channel blocker rheumatoid arthritis 2008 2008 R&I AZD9056 ion channel blocker COPD 2008 2008 R&I AZD8955 collagenase inhibitor osteoarthritis 2008 2008 R&I AZD3778 chemokine receptor antagonist rhinitis 2008 2008 Infection CytoFab Protherics anti-TNF-alpha polyclonal antibody severe sepsis 2008 2008 PHASE 2: LINE EXTENSIONS GI Nexium proton pump inhibitor extra-oesophageal reflux disease 2008 2008 Oncology Iressa EGFR-TK inhibitor breast cancer 2008 2008 PHASE 3: NCEs 5 5 CV Galida PPAR agonist diabetes metabolic syndrome 2H 2007 2H 2007 CV AGI-1067 AtheroGenics anti-atherogenic atherosclerosis 1H 2007 1H 2007 CV AZD6140 ADP receptor antagonist arterial thrombosis 2008 2008 Neuroscience NX Y-059 previously Cerovive free radical trapping agent stroke 1H 2007 1H 2007 Oncology Zactima ZD6474 VEGF EGF TKI inhibitor with RET kinase activity NSCLC 2008 2008 Oncology AZD2171 VEGF signalling inhibitor VEGFR-TKI NSCLC and CRC 2008 2008 PHASE 3: LINE EXTENSIONS CV Atacand angiotensin II antagonist diabetic retinopathy 2008 2008 CV Crestor statin atherosclerosis 1H 2007 1H 2007 CV Crestor statin outcomes CHF 2008 2008 CV Crestor statin outcomes renal 2008 2008 CV Seloken Toprol-XL beta blocker HCTZ combination Launched Filed 1 2 CV Exanta thrombin inhibitor prevention of stroke in AF Filed Filed 3 GI Nexium proton pump inhibitor NSAID GI side effects symptom resolution Promotable Filed GI Nexium proton pump inhibitor NSAID GI side effects ulcer healing Launched Filed GI Nexium sachet formulation proton pump inhibitor GERD Q4 2006 Filed GI Nexium proton pump inhibitor peptic ulcer bleeding 2008 2008 Neuroscience Seroquel SR D 5HT antagonist schizophrenia 3Q 2006 3Q 2006 2 2 Neuroscience Seroquel D 5HT antagonist bipolar maintenance 2H 2007 1H 2007 2 2 Neuroscience Seroquel D 5HT antagonist bipolar depression 1H 2007 Filed 2 2 Neuroscience Seroquel SR D 5HT antagonist generalised anxiety disorder 2008 2H 2007 2 2 Neuroscience Seroquel SR D 5HT antagonist major depressive disorder 2008 2008 2 2 Oncology Faslodex oestrogen receptor antagonist second line after aromatase inhibitor failure 2008 2008 Oncology Faslodex oestrogen receptor antagonist first line advanced breast cancer 2008 2008 Oncology Faslodex oestrogen receptor antagonist adjuvant 2008 2008 Oncology Iressa EGFR-TK inhibitor head and neck cancer 2H 2007 1H 2007 R&I Symbicort Turbuhaler inhaled steroid fast onset, long-acting 2 agonist SMART Filed 4 R&I Symbicort pMDI inhaled steroid fast onset, long-acting 2 agonist asthma Filed Filed 4 R&I Symbicort pMDI inhaled steroid fast onset, long-acting 2 agonist COPD Filed 2008 Infection Merrem carbapenem antibiotic skin and soft tissue infections Launched Comment: As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
1 Switched to EU centralised procedure.
2 AstraZeneca continues discussions with the FDA but the current assessment is that it is unlikely that a way forward for Exanta registration in the US will be identified.
3 Authorities stated these symptoms were already captured within the GERD label.
Text stating No clinical interaction with naproxen and rofecoxib was approved.
4 To be supplemented in 2008 with data supporting two additional strengths.
5 Subject to the results of phase 3 studies and regulatory discussions.
